Published online before print February 7, 2005, doi: 10.1161/01.CIR.0000155251.03724.A5
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:747-753.)
© 2005 American Heart Association, Inc.
Coronary Heart Disease |
Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification
From the Barbara Davis Center for Childhood Diabetes (D.M.M., P.W., M.R.), Department of Preventive Medicine and Biometrics (L.G.O., G.L.K., J.K.S.-B., D.D., J.E.H., M.R.), and Department of Medicine (R.H.E.), University of Colorado Health Sciences Center, and Colorado Heart Imaging (J.E.), Denver, Colo.
Correspondence to David M. Maahs, MD, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 E 9th Ave, Denver, CO 80262. E-mail David.Maahs{at}uchsc.edu
Received August 17, 2004; revision received November 23, 2004; accepted November 29, 2005.
Background— Circulating adiponectin levels are lower in men than in women and lower in advanced coronary artery disease, obesity, and type 2 but not type 1 diabetes. However, it is not known whether low adiponectin levels predict development of atherosclerosis independently of other cardiovascular risk factors.
Methods and Results— Progression of coronary artery calcification (CAC) over an average of 2.6 years (range, 1.6 to 3.3) was assessed in a cohort of patients with type 1 diabetes and nondiabetic subjects 19 to 59 years of age. In this nested case-control substudy, plasma adiponectin levels were measured in 101 cases with significant CAC progression and in 205 controls. Controls were oversampled on the basis of age, gender, diabetes status, and presence of baseline CAC. In conditional logistic regression adjusted for baseline CAC volume and other significant predictors of CAC progression, adiponectin levels were inversely related to progression of CAC in diabetic (OR, 0.47; 95% CI, 0.24 to 0.94) and nondiabetic (OR, 0.15; 95% CI, 0.05 to 0.40 for a doubling in adiponectin levels) subjects. Adjustment for additional cardiovascular risk factors did not change this association. In conditional logistic regression models by quartiles of plasma adiponectin levels, the probability value for trend was statistically significant for all participants (P<0.001) and nondiabetic participants (P<0.001) and was borderline for type 1 diabetics (P=0.08).
Conclusions— Low plasma adiponectin levels are associated with progression of CAC in type 1 diabetic and nondiabetic subjects independently of other cardiovascular risk factors.
Key Words: adiponectin • coronary disease • diabetes mellitus • epidemiology • risk factors
This article has been cited by other articles:
 |
|
 |
|
  A. Qasim, N. N. Mehta, M. G. Tadesse, M. L. Wolfe, T. Rhodes, C. Girman, and M. P. Reilly Adipokines, insulin resistance, and coronary artery calcification. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Skurk, F. Wittchen, L. Suckau, H. Witt, M. Noutsias, H. Fechner, H.-P. Schultheiss, and W. Poller Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy Eur. Heart J., May 1, 2008; 29(9): 1168 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-K. Son, M. Akishita, K. Iijima, K. Kozaki, K. Maemura, M. Eto, and Y. Ouchi Adiponectin Antagonizes Stimulatory Effect of Tumor Necrosis Factor-{alpha} on Vascular Smooth Muscle Cell Calcification: Regulation of Growth Arrest-Specific Gene 6-Mediated Survival Pathway by Adenosine 5'-Monophosphate-Activated Protein Kinase Endocrinology, April 1, 2008; 149(4): 1646 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rao, L. Li, H. Tighiouart, B. L. Jaber, B. J. G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Plasma adiponectin levels and clinical outcomes among haemodialysis patients Nephrol. Dial. Transplant., March 11, 2008; (2008) gfn070v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Williams, G. Qiu, H. K. Usui, S. R. Dunn, P. McCue, E. Bottinger, R. V. Iozzo, and K. Sharma Decorin Deficiency Enhances Progressive Nephropathy in Diabetic Mice Am. J. Pathol., November 1, 2007; 171(5): 1441 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Maahs, L. G. Ogden, J. K. Snell-Bergeon, G. L. Kinney, R. P. Wadwa, J. E. Hokanson, D. Dabelea, A. Kretowski, R. H. Eckel, and M. Rewers Determinants of Serum Adiponectin in Persons with and without Type 1 Diabetes Am. J. Epidemiol., September 15, 2007; 166(6): 731 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fantuzzi and T. Mazzone Adipose Tissue and Atherosclerosis: Exploring the Connection Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 996 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-J. Li, H.-W. Sun, F.-L. Zhu, L. Chen, Y.-Y. Rong, Y. Zhang, and M. Zhang Local adiponectin treatment reduces atherosclerotic plaque size in rabbits J. Endocrinol., April 1, 2007; 193(1): 137 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kretowski, K. McFann, J. E. Hokanson, D. Maahs, G. Kinney, J. K. Snell-Bergeon, R. P. Wadwa, R. H. Eckel, L. Ogden, S. Garg, et al. Polymorphisms of the Renin-Angiotensin System Genes Predict Progression of Subclinical Coronary Atherosclerosis Diabetes, March 1, 2007; 56(3): 863 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Orchard, T. Costacou, A. Kretowski, and R. W. Nesto Type 1 diabetes and coronary artery disease. Diabetes Care, November 1, 2006; 29(11): 2528 - 2538. [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig, N. Khuseyinova, J. Baumert, C. Meisinger, and H. Lowel Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men: Results From the 18-Year Follow-Up of a Large Cohort From Southern Germany J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1369 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S Mantzoros, C. J Williams, J. E Manson, J. B Meigs, and F. B Hu Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am. J. Clinical Nutrition, August 1, 2006; 84(2): 328 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pischon and E. B. Rimm Adiponectin: a promising marker for cardiovascular disease. Clin. Chem., May 1, 2006; 52(5): 797 - 799. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Knobler, M. Benderly, V. Boyko, S. Behar, Z. Matas, A. Rubinstein, I. Raz, and J. Wainstein Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose Eur. J. Endocrinol., January 1, 2006; 154(1): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Jung, K.-H. Park, Y. M. Cho, S. S. Chung, H. J. Cho, S. Y. Cho, S. J. Kim, S. Y. Kim, H. K. Lee, and K. S. Park Resistin is secreted from macrophages in atheromas and promotes atherosclerosis Cardiovasc Res, January 1, 2006; 69(1): 76 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Langenberg, J. Bergstrom, G. A. Laughlin, and E. Barrett-Connor Ghrelin, Adiponectin, and Leptin Do Not Predict Long-term Changes in Weight and Body Mass Index in Older Adults: Longitudinal Analysis of the Rancho Bernardo Cohort Am. J. Epidemiol., December 15, 2005; 162(12): 1189 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Libby, D. M. Nathan, K. Abraham, J. D. Brunzell, J. E. Fradkin, S. M. Haffner, W. Hsueh, M. Rewers, B. T. Roberts, P. J. Savage, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus Circulation, June 28, 2005; 111(25): 3489 - 3493. [Full Text] [PDF]
|
|